Olumiant
Developed to support immune system regulation and to address symptoms of autoimmune conditions.
- Category
- Autoimmune Support
- Active ingredient
- Baricitinib
- Supply
- Rx
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 4mg
Olumiant details
- Conditions
- Rheumatoid Arthritis · Atopic Dermatitis · Alopecia Areata
- Therapeutic class
- Janus Kinase (JAK) Inhibitor
- Pharmacological class
- JAK Inhibitor
- Contraindications
- hypersensitivity to baricitinib; pregnancy; severe active infections
- Minor side effects
- nausea; upper respiratory tract infection
- Moderate side effects
- herpes zoster infection; elevated liver enzymes
- Dosage forms
- Film-coated tablet
- Administration route
- Oral use
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- Eli Lilly
- Onset Time
- 1–3 hours
- Duration
- 24 hours
- Storage instructions
- Store below 30°C in the original packaging.
- Drug interactions
- probenecid; live vaccines
- Age restrictions
- Not for children.
- Pregnancy and breastfeeding
- Pregnancy: Not recommended. Breastfeeding: Avoid during treatment.
Precautions and warnings
screen for tuberculosis prior to initiation; regular blood monitoring recommended
Serious side effects
venous thromboembolism, requires immediate medical attention; serious infection, requires immediate medical attention
Patient summary
Developed to support immune system regulation and to address symptoms of autoimmune conditions.
Mechanism of action
Baricitinib is a reversible inhibitor of Janus kinases (JAK1 and JAK2). It interrupts the signaling pathways of cytokines involved in inflammatory processes, thereby reducing immune-mediated damage.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Olumiant
Olumiant is the brand name for baricitinib, a medication used in the management of rheumatoid arthritis, atopic dermatitis and alopecia areata. This treatment belongs to a class of medicines known as Janus kinase inhibitors and is supplied as a 4mg tablet. It is developed and produced by Eli Lilly.
Olumiant availability in Asia
Olumiant is authorised for use across 14 distinct markets, including Malaysia, the Philippines and Indonesia. Availability extends further into territories such as Taiwan, South Korea and Japan. As effective as these therapies may be, this medication is best used under a doctor’s care to monitor progress and manage potential side effects. Patients often find this supply helpful when living away from home or in locations where maintaining a consistent routine for chronic conditions can be challenging.